CD19 and mantle cell lymphoma: This group has conducted a phase IIa clinical trial of CTL019 cells in patients with relapsed or refractory CD19+ non-Hodgkin lymphomas (NCT02030834); 29 patients (19 DLBCL; 8 FL; 2 MCL) enrolled and 20 patients received CTL019 per protocol dose (12 DLBCL; 7 FL; 1 MCL).